MERGERSCORP

美国领先的生命科学研究

PRINTED ON: *August 8, 2026, 2:21 AM (EST)* **PUBLISHED ON:** *August 8, 2026, 1:21 AM (EST)* **UPDATED ON:** *August 8, 2026, 1:21 AM (EST)*

MERGERSCORP

TARGET PRICE

$ 44,000,000

GROSS REVENUE

$ 57,000,000

EBITDA

$ 3,700,000

BUSINESS TYPE

制造业

COUNTRY

美国

BUSINESS ID

L#20261103

美洲地区一家领先的独立多组学服务提供商。
该公司为北美和南美的研究机构、医院、生物技术公司及制药企业提供涵盖新一代测序（NGS）、蛋白质组学、代谢组学、表观基因组学及生物信息学的全面解决方案组合。交易完成后，公司将成为一个完全独立的平台，在有机扩张、运营优化和战略收购方面将拥有巨大的机遇。

投资亮点

1. 吸引人的高增长精准医疗投资机会

在全球精准医学、药物研发、肿瘤学、基因组学研究以及制药公司外包需求不断增加的推动下，全球测序服务市场继续以约20%的复合年增长率（CAGR）扩张。

本公司处于极其有利的地位，能够充分利用这些结构性增长趋势。

2. 美洲地区公认的市场领导者

- 当地实验室运营
- 美洲各地的销售团队
- 全面的服务方案
- 在研究机构中享有盛誉
- 可扩展的运营平台

3. 优质客户群

深受顶尖大学、医院和全球制药公司的信赖，包括：

- 斯坦福大学
- 加州大学
- 艾伯维
- 辉瑞
- 阿斯利康
- 诺和诺德
- 安进
- 百时美施贵宝
- 吉利德
- 赛诺菲

4. 专有实验室自动化系统

公司已在专有实验室自动化领域投入了大量资金，从而实现了：

- 生产周期缩短60%
- 每条生产线每天400个样本
- 产能提高25%
- 生产率提高100%
- 业界领先的测序质量

这些能力不仅构成了实质性的市场准入壁垒，同时还能支撑强大的经营杠杆效应。

5. 高度多元化的服务组合

该平台提供涵盖以下领域的端到端解决方案：

- 新一代测序
- 单细胞测序
- 表观基因组学
- 元基因组学
- 蛋白质组学
- 代谢组学
- 生物信息学
- 定制研究服务

6. 经验丰富的科学管理团队

该公司由一支经验丰富的科学领导团队领导，该团队在分子生物学、基因组学、实验室运营和商业开发方面拥有深厚的专业知识。

预计现有管理团队将在交易完成后确保运营的连续性。

7. 巨大的价值创造潜力

在从其上市母公司分拆后，投资者将从中获益：

- 独立的战略方向
- 业务优化
- 提高利润率举措
- 地域扩张
- 新实验室建设
- 潜在的补充性收购
- 长期首次公开募股（IPO）或战略退出机会

交易概述

机遇

收购了一家总部位于美国的领先多组学平台的控股权。

卖家

一家在公开市场上市的跨国公司。

交易结构

灵活的交易结构，包括股权收购和/或首次资本注入。

预计成交时间

2026年第四季度。

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

MERGERSCORP